Host genomic DNA (DNA)

Host genomic DNA is the macromolecule that stores the complete set of genetic instructions necessary for the development, functioning, and reproduction of an organism (NIH: Genetics Home Reference). In a therapeutic context, it serves as a major target for various classes of drugs, particularly in oncology and genetic medicine. Traditional chemotherapeutic agents, such as alkylating agents and platinum-based compounds, interact with DNA to form covalent adducts or cross-links, which interfere with replication and transcription, leading to cell cycle arrest and apoptosis (PMID: 15591301). More recently, the advent of gene-editing technologies like CRISPR-Cas9 has allowed for the direct modification of specific sequences within the host genome to treat hereditary diseases (FDA, 2023). DNA's role in disease is central, as mutations, chromosomal translocations, and epigenetic modifications are primary drivers of cancer and various genetic syndromes (Nature Reviews Cancer, 2020). However, targeting genomic DNA presents significant challenges, including the risk of inducing secondary malignancies through non-specific damage and the potential for permanent, unintended off-target genetic alterations (StatPearls: Cancer Chemotherapy).

Other names

Genomic DNANuclear DNAChromosomal DNAHuman genomeDeoxyribonucleic acid

Drugs targeting host genomic DNA typically act through covalent binding (alkylation), cross-linking of DNA strands, intercalation between base pairs, or the induction of double-strand breaks to inhibit replication and transcription, ultimately triggering apoptosis (PMID: 15591301, StatPearls: Alkylating Agents). Modern gene-editing therapies utilize site-specific nucleases to induce targeted breaks, allowing for the correction or disruption of specific genetic sequences through endogenous repair mechanisms (FDA, 2023).